Answer
The gastrointestinal adverse reactions classed as very common (≥1/10) with dinutuximab beta are vomiting, diarrhoea, constipation and stomatitis.
Sources for this answer
- Qarziba (Dinutuximab beta)Recordati UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 13Document updated
Sources checked